197 related articles for article (PubMed ID: 34845227)
1. Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer.
Munne PM; Martikainen L; Räty I; Bertula K; Nonappa ; Ruuska J; Ala-Hongisto H; Peura A; Hollmann B; Euro L; Yavuz K; Patrikainen L; Salmela M; Pokki J; Kivento M; Väänänen J; Suomi T; Nevalaita L; Mutka M; Kovanen P; Leidenius M; Meretoja T; Hukkinen K; Monni O; Pouwels J; Sahu B; Mattson J; Joensuu H; Heikkilä P; Elo LL; Metcalfe C; Junttila MR; Ikkala O; Klefström J
Nat Commun; 2021 Nov; 12(1):6967. PubMed ID: 34845227
[TBL] [Abstract][Full Text] [Related]
2. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
4. p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis.
Anwar T; Arellano-Garcia C; Ropa J; Chen YC; Kim HS; Yoon E; Grigsby S; Basrur V; Nesvizhskii AI; Muntean A; Gonzalez ME; Kidwell KM; Nikolovska-Coleska Z; Kleer CG
Nat Commun; 2018 Jul; 9(1):2801. PubMed ID: 30022044
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast carcinogenesis.
Cao LB; Ruan ZL; Yang YL; Zhang NC; Gao C; Cai C; Zhang J; Hu MM; Shu HB
J Mol Cell Biol; 2024 Jan; 15(7):. PubMed ID: 37442610
[TBL] [Abstract][Full Text] [Related]
6. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
[TBL] [Abstract][Full Text] [Related]
7. Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer.
Andruska N; Zheng X; Yang X; Helferich WG; Shapiro DJ
Oncogene; 2015 Jul; 34(29):3760-9. PubMed ID: 25263449
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
12. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
[TBL] [Abstract][Full Text] [Related]
13. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
14. Estradiol regulates Tumor Necrosis Factor-α expression and secretion in Estrogen Receptor positive breast cancer cells.
To SQ; Cheung V; Lazarus KA; Knower KC; Clyne CD
Mol Cell Endocrinol; 2014 Aug; 394(1-2):21-8. PubMed ID: 25004254
[TBL] [Abstract][Full Text] [Related]
15. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
16. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
17. ERE-independent ERalpha target genes differentially expressed in human breast tumors.
Glidewell-Kenney C; Weiss J; Lee EJ; Pillai S; Ishikawa T; Ariazi EA; Jameson JL
Mol Cell Endocrinol; 2005 Dec; 245(1-2):53-9. PubMed ID: 16298037
[TBL] [Abstract][Full Text] [Related]
18. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
[TBL] [Abstract][Full Text] [Related]
19. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
Long X; Fan M; Bigsby RM; Nephew KP
Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
[TBL] [Abstract][Full Text] [Related]
20. The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.
Jiang Z; Guo J; Shen J; Jin M; Xie S; Wang L
J Exp Clin Cancer Res; 2012 May; 31(1):42. PubMed ID: 22553917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
